1-甲基-3-(2-硝基苯基)脲 | 53414-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲基-3-(2-硝基苯基)脲
• 英文名称: N-methyl-N'-(2-nitro-phenyl)-urea
• 英文别名: N-Methyl-N'-(2-nitro-phenyl)-harnstoff；1-Methyl-3-(2-nitrophenyl)urea
• CAS: 53414-34-9
• 化学式: C₈H₉N₃O₃
• 分子量: 195.178
• InChiKey: KCOLNOFMUIWWEY-UHFFFAOYSA-N

物化性质

• 沸点：
  313.8±34.0 °C(Predicted)
• 密度：
  1.363±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  87
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-甲基-3-(2-硝基苯基)脲 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium nitrite 作用下， 以 甲醇 、 水 为溶剂， 反应 0.33h， 生成 N-Methyl-1H-benzotriazole-1-carboxamide
  参考文献：
  名称：

  Bertrand, J. Jean-Claude; Just, George, Journal of the Chemical Society. Perkin transactions I, 1991, # 10, p. 2525 - 2529

  摘要：

  DOI：
• 作为产物：
  描述：

  N-methyl-N'-(2-nitro-benzenesulfonyl)-urea 、 alkaline earth salt of/the/ methylsulfuric acid 生成 1-甲基-3-(2-硝基苯基)脲
  参考文献：
  名称：

  Backer; Groot, Recueil des Travaux Chimiques des Pays-Bas, 1950, vol. 69, p. 1323,1343

  摘要：

  DOI：

文献信息

• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US10351522B2

  公开（公告）日：2019-07-16

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，该化合物具有奥曲肽受体激动剂活性，有望用作嗜睡症等的预防或治疗药物。本发明提供了一种由式（I）代表的化合物： 其中各符号如描述中所定义，或其药学上可接受的酸加成盐，具有奥曲肽受体激动剂活性，以及含有该化合物或其药学上可接受的酸加成盐的奥曲肽受体激动剂。
• Oil gelator
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US10640462B2

  公开（公告）日：2020-05-05

  There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): wherein R1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C1-10 alkyl group, a C1-10 alkoxy group, a C6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C2-10 alkylcarbonyl group, and a C7-18 aralkyl group.

  本发明提供了一种含有单脲衍生物的新型凝胶剂。凝胶剂包含式（1）化合物： 其中 R1 是碳原子数为 2 至 20 的直链或支链烷基、碳原子数为 3 至 20 的环状烷基或碳原子数为 12 至 20 的直链或支链烯基；Ar是未取代的C6-18芳基，或任选被至少一个取代基取代，该取代基选自由 C1-10烷基、C1-10烷氧基、C6-18芳氧基、卤素原子、硝基、苯基、C2-10烷基羰基和C7-18芳烷基组成的组。
• Scholl; Nyberg, Chemische Berichte, 1906, vol. 39, p. 2491
  作者：Scholl、Nyberg

  DOI：——

  日期：——
• Inhibitors of c-Jun N-terminal kinases (JNK)
  申请人：Salituro G. Francesco

  公开号：US20080033022A1

  公开（公告）日：2008-02-07

  The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.